15kD Granulysin for Monocyte Differentiation: A New Immunotherapeutic for Both in vivo and ex vivo Applications


Granulysin is a cytolytic and proinflammatory molecule expressed by activated human cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. It has been implicated in many of diseases including infection, cancer, transplantation, autoimmunity, skin and reproductive maladies. Small synthetic forms of granulysin are being developed as novel antibiotics and studies suggest that granulysin may be a useful diagnostic biomarker and/or therapeutic for a wide variety of diseases.

The invention relates to methods of stimulating or enhancing an immune response using 15 kD granulysin. Investigators at the NIH have discovered that 15 kD granulysin (but not 9 kD granulysin) activates monocytes and induces them to differentiate into mature dendritic cells and activates allospecific T cells. This activation and subsequent differentiation induced by 15 kD granulysin may prove important in inducing or regulating immune responses in a host. Consequently, this invention could be used to treat tumors and infections, particularly as an adjuvant for vaccines and immunotherapies. Further, this technology could be used to treat autoimmune disorders and organ transplant rejection.

The National Cancer Institute, Laboratory of Cellular and Molecular Biology, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.



Potential Commercial Applications: Competitive Advantages:

• Stimulating immunity to vaccinations, tumors or infections
• Blocking the induction of an immune response in an autoimmune disease or organ transplant rejection

 

• An immune response activator with broad applicability to the treatment of several diseases, including cancer, atherosclerosis, diabetes, autoimmune disorders, allergies, and infections
• Co-administering 15kD granulysin could increase the efficacy of vaccines and immunotherapeutics



Development Stage:
Pre-clinical (in vivo)

Inventors:

Alan Krensky (NCI)  ➽ more inventions...

Carol Clayberger (NCI)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8815229 issued 2014-08-26
U.S. Pat: 9385285 issued 2016-06-07
U.S. Pat: 2010307075 issued 2015-04-02

Publications:
Stenger S, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. PMID 9756476
Castiello L, et al. 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level. PMID 21501511
Tewary P, et al. Granulysin activates antigen-presenting cells through TLR4 and acts as an immune alarmin. PMID 20660289

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-158-2009
Updated: Oct 10, 2017